168 related articles for article (PubMed ID: 33025342)
1. Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
Tran JQ; Zhang P; Walker S; Ghosh A; Syto M; Wang X; Harris S; Palmisano M
Adv Ther; 2020 Dec; 37(12):4944-4958. PubMed ID: 33025342
[TBL] [Abstract][Full Text] [Related]
2. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
[TBL] [Abstract][Full Text] [Related]
3. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
Surapaneni S; Yerramilli U; Bai A; Dalvie D; Brooks J; Wang X; Selkirk JV; Yan YG; Zhang P; Hargreaves R; Kumar G; Palmisano M; Tran JQ
Drug Metab Dispos; 2021 May; 49(5):405-419. PubMed ID: 33674268
[TBL] [Abstract][Full Text] [Related]
4. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
Briggs E; Chapel S; Zhang P; Palmisano M; Tran JQ
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):119-126. PubMed ID: 33314790
[TBL] [Abstract][Full Text] [Related]
5. Investigation into MAO B-Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (
Bai A; Shanmugasundaram V; Selkirk JV; Surapaneni S; Dalvie D
Drug Metab Dispos; 2021 Aug; 49(8):601-609. PubMed ID: 34011531
[TBL] [Abstract][Full Text] [Related]
6. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
Tran JQ; Hartung JP; Tompkins CA; Frohna PA
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):634-640. PubMed ID: 29125718
[TBL] [Abstract][Full Text] [Related]
7. Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.
Tran JQ; Hartung JP; Peach RJ; Boehm MF; Rosen H; Smith H; Brooks JL; Timony GA; Olson AD; Gujrathi S; Frohna PA
J Clin Pharmacol; 2017 Aug; 57(8):988-996. PubMed ID: 28398597
[TBL] [Abstract][Full Text] [Related]
8. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
Harris S; Tran JQ; Southworth H; Spencer CM; Cree BAC; Zamvil SS
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
[TBL] [Abstract][Full Text] [Related]
9. Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.
Tran JQ; Hartung JP; Olson AD; Mendzelevski B; Timony GA; Boehm MF; Peach RJ; Gujrathi S; Frohna PA
Clin Pharmacol Drug Dev; 2018 Mar; 7(3):263-276. PubMed ID: 28783871
[TBL] [Abstract][Full Text] [Related]
10. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
Selkirk JV; Yan YG; Ching N; Paget K; Hargreaves R
Eur J Pharmacol; 2023 Feb; 941():175442. PubMed ID: 36470447
[TBL] [Abstract][Full Text] [Related]
11. In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.
Flanagan S; Bartizal K; Minassian SL; Fang E; Prokocimer P
Antimicrob Agents Chemother; 2013 Jul; 57(7):3060-6. PubMed ID: 23612197
[TBL] [Abstract][Full Text] [Related]
12. Single-dose and steady-state bioequivalence of fexofenadine and pseudoephedrine combination tablets compared with individual formulations in healthy adults.
Howard DR; Haribhakti R; Kittner B; Agrawala P
Curr Med Res Opin; 2005 May; 21(5):769-76. PubMed ID: 15969876
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled, exploratory trial of Ibuprofen and pseudoephedrine in the treatment of primary nocturnal enuresis in children.
Gelotte CK; Prior MJ; Gu J
Clin Pediatr (Phila); 2009 May; 48(4):410-9. PubMed ID: 19258524
[TBL] [Abstract][Full Text] [Related]
14. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor.
Thébault JJ; Guillaume M; Levy R
Pharmacotherapy; 2004 Oct; 24(10):1295-305. PubMed ID: 15628826
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
Azzaro AJ; VanDenBerg CM; Ziemniak J; Kemper EM; Blob LF; Campbell BJ
J Clin Pharmacol; 2007 Aug; 47(8):978-90. PubMed ID: 17554106
[TBL] [Abstract][Full Text] [Related]
16. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
[TBL] [Abstract][Full Text] [Related]
18. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
Sandborn WJ; Feagan BG; Wolf DC; D'Haens G; Vermeire S; Hanauer SB; Ghosh S; Smith H; Cravets M; Frohna PA; Aranda R; Gujrathi S; Olson A;
N Engl J Med; 2016 May; 374(18):1754-62. PubMed ID: 27144850
[TBL] [Abstract][Full Text] [Related]
19. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Tedizolid and Pseudoephedrine Administered Alone or in Combination in Healthy Volunteers.
Flanagan S; Minassian SL; Prokocimer P
J Clin Med; 2018 Jun; 7(6):. PubMed ID: 29899212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
